

Exploiting novel biology to gain **revolutionary power over cancer**

Angiex is developing **first-in-class Nuclear-Delivered Antibody-Drug Conjugates™** to address the hallmarks of cancer lethality. Angiex's lead drug, AGX101, is a TM4SF1-directed ND-ADC with maytansine payload.

AGX101:

A potentially transformative therapy for all solid cancer patients

📌 Novel and differentiated biology


TM4SF1 is a novel ADC target which was clinically validated as a radioimmunotherapy target. TM4SF1 offers remarkable tumor homing, with up to 70% of antigen in the tumor; and the ability to attack two compartments of the tumor – the angiogenic tumor vasculature and the tumor cells.

📌 Highly optimized drug

Angiex's lead drug, AGX101, is highly optimized, the result of twenty-three years of biology research and thirteen years of drug development. AGX101 has freedom to operate and is protected by a dozen patents.

📌 Three novel and potent mechanisms of efficacy

AGX101 has three novel and potent mechanisms of action: (1) depriving tumors of their blood supply, (2) activation of anti-tumor immunity, and (3) direct killing of tumor cells.



📌 Outstanding safety

In monkeys, AGX101 has no observed adverse effect at the highest single-dose level tested, 40 mg/kg. Measured by exposure, preclinical therapeutic margin is the best yet seen in an oncology drug. In Phase 1 clinical studies, AGX101 activity has been on-target and largely on-tumor.


📌 Excellent clinical progress to date in the Phase 1 Trial

AGX101 has completed a first pass through its dose escalation, safely clearing the first five dose levels and dosing as high as 8 mg/kg. There is encouraging clinical evidence of pharmacodynamic effect from 2 mg/kg upward. At lower doses AGX101 has prevented tumor growth for up to 10 months. Angiex expects patient responses to be demonstrated in early 2026.

Clinical plan

AGX101 Phase 1 trial

An all-comers dose escalation with expansions in selected indications, and combination arms with pembrolizumab and ipilimumab.
CRO: Medpace. Sites: Sarah Cannon (Nashville, TN), NEXT Oncology (San Antonio, TX; Fairfax, VA), Univ of Southern California (Los Angeles), Washington Univ of St Louis (St Louis MO), Florida Cancer Specialists (Sarasota FL), MD Anderson Cancer Center (Houston TX)



Team

Founded by leading scientists in angiogenesis, including the discoverer of VEGF-A, Angiex is led by experienced entrepreneurs and renowned scientific and ADC drug development leaders.



Paul Jaminet, PhD
Founder & CEO

- Founder & President 2015-present
- Experienced scientist-entrepreneur, best-selling author
- PhD in Physics, University of California, Berkeley; Astrophysicist, Harvard-Smithsonian Center for Astrophysics
- Founded 4 companies, successful exit



Iain Dukes, DPhil
Executive Chair

- Venture Partner, Orbimed Advisors
- CEO of Viriom, Theseus Pharmaceuticals, Chairman of KaNDy Therapeutics, Iovance Biotherapeutics
- Former Merck SVP Business Development, VP External R&D Amgen



Glen Weiss, MD
Chief Medical Officer

- Former CMO, Quibim, and VP of Clinical Sciences, SOTIO Biotech
- Former Director of Phase 1 Research, Beth Israel Deaconess Medical Center, and faculty, Harvard Medical School



Brian Clark
Head of Manufacturing

- Former VP Manufacturing and Quality, Immunogen
- Genzyme, Altus Pharma, Alkermes, Therion Bio, Agenus
- CMC leader for two FDA-approved drugs and ADCs



Jeff Sacher
Chief Financial Officer

- Four-time biotech CFO and biotech founder
- 25 years in investment banking at Goldman Sachs and as Head of Life Sciences, National Securities



Advisors

- Harold F. Dvorak, MD
- Shou-Ching Jaminet, PhD
- Morris Rosenberg
- Geoff Shapiro, MD, PhD
- Brad Pentelute, PhD
- Mike Sun, PhD

Opportunity

Angiex may have opportunities for accredited investors to help fund the clinical development of AGX101, or for cancer patients to join our clinical trial. To find out if such opportunities are available, please contact Angiex's investor relations team at invest@angiex.com, or the study site contacts listed at **NCT06440005**.